TargetBeta
APP
amyloid beta precursor protein · also alpha-sAPP, AD1 · Receptor ligands
3 programs in company-led studies act on APP, from 2 companies: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
Conditions their studies are in
- Alzheimer Disease, 3 programs
- Cognitive Dysfunction, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2027donanemab · Eli Lilly · phase 4 · NCT05026866
- Oct 2030ABBV-1758 · AbbVie · phase 2 · NCT07599670
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.